In this video, Professor François Roubille (University Hospital Arnaud de Villeneuve, Montpellier, France) joins Associate Professor Ruxandra Christodorescu (University of Medicine and Pharmacy Victor Babes, Timisoara, Romania; Past Chairperson Board of the ESC Council for Cardiology Practice) to discuss inflammation and coronary artery disease.
Inflammation and coronary artery disease: what we know so far and what can be done to reduce it?
References
- Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377:1119-31.
- Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505.
- Nidorf SM, Fiolet ATL, Mosterd A, et al; LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med.;383:1838-1847.
- Tardif JC, Kouz S. Efficacy and safety of colchicine and spironolactone after myocardial infarction: the CLEAR-SYNERGY trial in perspective. Eur Heart J Acute Cardiovasc Care. 2024;13:843-4.
- Byrne RA, Rossello X, Coughlan JJ, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720-826.
- Vrints C, Andreotti F, Koskinas KC, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415-3537.
